Literature DB >> 20391270

Psychotropic medications and substances of abuse interactions in youth.

Yifrah Kaminer1, Pablo Goldberg, Daniel F Connor.   

Abstract

The majority of youth with substance use disorders (SUDs) manifest one or more co-occurring psychiatric disorders. Consequently, many of these youths are being prescribed with psychotropic medications. As prescribing rates continue to increase for early-onset psychiatric disorders, potential risk for substance of abuse-psychiatric medication interactions may be enhanced. Because this type of drug-drug interaction has received little attention in the scientific literature, the authors conducted a systematic literature search examining the potential interactive adverse effects between psychotropic medications and substances of abuse in youth. Regardless of the scarcity of psychotropic medications-substance of abuse interactions found, it is important to stay vigilant due to the continued introduction of new classes of medications as well as the ever-changing map of street drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20391270      PMCID: PMC3145318          DOI: 10.1080/08897070903442665

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  18 in total

1.  The use of antidepressants among injecting drug users in Sydney, Australia.

Authors:  S Darke; J Ross
Journal:  Addiction       Date:  2000-03       Impact factor: 6.526

Review 2.  The reality of comorbidity: depression and drug abuse.

Authors:  Nora D Volkow
Journal:  Biol Psychiatry       Date:  2004-11-15       Impact factor: 13.382

3.  Drugs of abuse in the future.

Authors:  A T Shulgin
Journal:  Clin Toxicol       Date:  1975       Impact factor: 4.467

4.  Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants.

Authors:  T E Wilens; J Biederman; T J Spencer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-01       Impact factor: 8.829

5.  Risk factors for adolescent suicide. A comparison of adolescent suicide victims with suicidal inpatients.

Authors:  D A Brent; J A Perper; C E Goldstein; D J Kolko; M J Allan; C J Allman; J P Zelenak
Journal:  Arch Gen Psychiatry       Date:  1988-06

Review 6.  The self-medication hypothesis of substance use disorders: a reconsideration and recent applications.

Authors:  E J Khantzian
Journal:  Harv Rev Psychiatry       Date:  1997 Jan-Feb       Impact factor: 3.732

7.  The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance.

Authors:  J S Kerr; J Powell; I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1996-08       Impact factor: 4.335

8.  Completed suicide and psychiatric diagnoses in young people: a critical examination of the evidence.

Authors:  Alexandra Fleischmann; José Manoel Bertolote; Myron Belfer; Annette Beautrais
Journal:  Am J Orthopsychiatry       Date:  2005-10

Review 9.  Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.

Authors:  Jack R Cornelius; Duncan B Clark; Oscar G Bukstein; Boris Birmaher; Ihsan M Salloum; Sandra A Brown
Journal:  Addict Behav       Date:  2005-08-15       Impact factor: 3.913

10.  Psychiatric diagnoses as contemporaneous risk factors for suicide attempts among adolescents and young adults: developmental changes.

Authors:  David B Goldston; Stephanie Sergent Daniel; Alaattin Erkanli; Beth A Reboussin; Andrew Mayfield; Patricia H Frazier; Sarah L Treadway
Journal:  J Consult Clin Psychol       Date:  2009-04
View more
  2 in total

1.  Pharmacotherapy for adolescent alcohol use disorder.

Authors:  Duncan B Clark
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 2.  Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs.

Authors:  Jon Jureidini; Anne Tonkin; Elsa Jureidini
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.